Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells

Journal of Clinical Medicine

Kwong-Man Ng¹  Cheuk-Yiu Law¹  Hung-Fat Tse¹ 

[1] Cardiology Division, Department of Medicine, Rm. 1928, Block K, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China; E-Mails:

关键词: patient-specific-iPSCs-derived cardiomyocytes;    regenerative medicine;    modeling of inherited cardiac disorder;    drug testing;    toxicology studies;   

DOI  :  10.3390/jcm3041105

来源: mdpi

【 摘 要 】

The lack of appropriate human cardiomyocyte-based experimental platform has largely hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into functional cardiomyocytes. This powerful reprogramming technology provides a novel in vitro human cell-based platform for the study of human hereditary cardiac disorders. The clinical potential of using iPSCs derived from patients with inherited cardiac disorders for therapeutic studies have been increasingly highlighted. In this review, the standard procedures for generating patient-specific iPSCs and the latest commonly used cardiac differentiation protocols will be outlined. Furthermore, the progress and limitations of current applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement therapy, disease modeling, drug-testing and toxicology studies will be discussed in detail.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.